

Financial news for PPHM dated on 2018-01-05: Peregrine Pharma Reports Change In Corporate Name To Avid Biosciences, Will Trade Under NASDAQ Ticker Symbol 'CDMO'

Financial news for PPHM dated on 2017-12-26: Peregrine Pharmaceuticals Names Dr. Roger Lias President, CEO

Financial news for PPHM dated on 2017-12-13: 40 Biggest Movers From Yesterday

Financial news for PPHM dated on 2017-12-12: Mid-Afternoon Market Update: Crude Oil Down 1.5%; Proteostasis Therapeutics Shares Spike Higher

Financial news for PPHM dated on 2017-12-12: 30 Stocks Moving In Tuesday's Mid-Day Session

Financial news for PPHM dated on 2017-12-12: Mid-Day Market Update: Dow Rises Over 100 Points; Oasis Petroleum Shares Plummet

Financial news for PPHM dated on 2017-12-12: Mid-Morning Market Update: Markets Mostly Higher; Casey's Earnings Miss Views

Financial news for PPHM dated on 2017-12-12: 30 Stocks Moving In Tuesday's Pre-Market Session

Financial news for PPHM dated on 2017-12-12: 7 Stocks To Watch For December 12, 2017

Financial news for PPHM dated on 2017-12-11: 7 Stocks Moving In Monday's After-Hours Session

Financial news for PPHM dated on 2017-12-11: Peregrine Pharma Reaffirms FY18 Manufacturing Sales \$50M-\$55M

Financial news for PPHM dated on 2017-12-11: Peregrine Pharma Reports Q2 EPS \$(0.31) vs \$(0.16) In Same Qtr. Last Year, Contract Manufacturing Sales \$12.782M vs \$23.37M YoY

Financial news for PPHM dated on 2017-12-11: Earnings Scheduled For December 11, 2017

Financial news for PPHM dated on 2017-11-28: Peregrine Pharmaceuticals, Ronin Trading and SW Investment Management Announce Settlement Agreement; Peregrine Board Reconstituted with Four New Independent Directors

Financial news for PPHM dated on 2017-10-31: Mid-Day Market Update: Trex Rises After Strong Q3 Results; Under Armour Shares Slide

Financial news for PPHM dated on 2017-10-30: UPDATE: Ronin 'Reiterates Demand for Peregrine to Hold 2017 Annual Meeting Immediately to Enable Stockholders to Elect Representatives of their Choosing'

Financial news for PPHM dated on 2017-10-30: UPDATE: Ronin On Peregrine Pharma 'Believes Recent Changes are Insufficient and Calls on Peregrine to Justify Long-Standing Incumbent Directors' Continued Service on the Board'

Financial news for PPHM dated on 2017-10-30: Peregrine Pharma Shares Tick Slightly Lower Amid Press Release From Ronin Trading, SW Highlighting 'Concerns With Board Of Peregrine'

Financial news for PPHM dated on 2017-09-11: Peregrine Pharma On Avid Bioservices: Despite 'lower manufacturing demand from our top two customers,' Still Sees \$50M-\$55M In FY18 Manufacturing Sales

Financial news for PPHM dated on 2017-09-11: Peregrine Pharma Highlights 'Supported by Recent Positive Data, Company is Pursuing Strategic Options for its Research and Development Assets'

Financial news for PPHM dated on 2017-09-11: Peregrine Pharma Reports Q1 EPS \$(0.06) vs \$(0.12) Est., Contract Manufacturing Sales \$27.077M

Financial news for PPHM dated on 2017-09-11: Earnings Scheduled For September 11, 2017

Financial news for PPHM dated on 2017-09-07: Peregrine Pharma Reports First Patient In Phase 2 Trial Evaluating Baviximab Treatment Combo In Patients With Newly Diagnosed Glioblastoma Dosed

Financial news for PPHM dated on 2017-07-31: Peregrine Expands Board of Directors To Seven Members, Continues To Evaluate Strategic Options For R&D Business

Financial news for PPHM dated on 2017-07-17: Mid-Afternoon Market Update: Peregrine Pharma Drops After Q4 Results; Quidel Shares Jump

Financial news for PPHM dated on 2017-07-17: 12 Biggest Mid-Day Losers For Monday

Financial news for PPHM dated on 2017-07-17: Mid-Day Market Update: Sevcon Surges Following Acquisition News; TherapeuticsMD Shares Slide

Financial news for PPHM dated on 2017-07-17: Mid-Morning Market Update: Markets Edge Higher; BlackRock Profit Misses Views

Financial news for PPHM dated on 2017-07-17: STAT News' Adam Feuerstein Tweets: \$PPHM disappoints once again? \$PPHM is in a constant state of disappointment. That will never change.

Financial news for PPHM dated on 2017-07-17: 6 Stocks To Watch For July 17, 2017

Financial news for PPHM dated on 2017-07-14: Peregrine Pharmaceuticals Reports Quarter Ended EPS \$(0.16) vs \$(0.40) In Prior Year Period, Sales \$17.9M vs \$18.7M In Prior Year Period

Financial news for PPHM dated on 2017-07-14: Earnings Scheduled For July 14, 2017

Financial news for PPHM dated on 2017-07-13: Peregrine Pharmaceuticals-Confirms Ronin Trading, SW Investment Management Submitted 3 Candidates for Election to Co's Board At Co's Annual General Meeting

Financial news for PPHM dated on 2017-07-13: Ronin Trading, LLC and SW Investment Management LLC Says Peregrine's Board Needs Change Due To Apparent Misalignment Of Interests With Stockholders and Constant Dilution

Financial news for PPHM dated on 2017-07-07: Peregrine Pharma Reports 1-for-7 Reverse Split Will Become Effective 5 p.m. EDT On July 7

Financial news for PPHM dated on 2017-07-07: Peregrine Pharmaceuticals Reports 1-for-7 Reverse Stock Split

Financial news for PPHM dated on 2017-06-05: UPDATE: Peregrine on SUNRISE Trial Says Presented Results Support Hypothesis that Bavituximab May Demonstrate Greater Effect in "Cold" Tumors Expressing Low to No PD-L1

Financial news for PPHM dated on 2017-06-05: Peregrine Pharma Reports Presentation of Prelim. Correlative Analysis of PD-L1 Expression from SUNRISE Trial: Negative PD-L1 Expression was Associated with a Significantly Longer Median Overall Survival

Financial news for PPHM dated on 2017-04-17: Ronin Capital Reports 5.8% Stake In Peregrine Pharmaceutical

Financial news for PPHM dated on 2017-04-12: Peregrine Pharmaceuticals, Inc. Received Letter From NASDAQ That They Will Delist Company's Securities From NASDAQ On April 20th

Financial news for PPHM dated on 2017-04-04: Peregrine Pharma Reports SUNRISE Data Shows Statistically Significant OS Improvement in Patients Receiving Bavituximab + Docetaxel, Subsequent Immunotherapy Compared to Placebo + Docetaxel

Financial news for PPHM dated on 2017-03-13: Peregrine Pharma Reports Q3 EPS \$(0.04) vs \$(0.03) Est., Sales \$10.747M vs \$6.709M in Same Qtr. Last Year

Financial news for PPHM dated on 2017-03-02: Ronin Capital Reports 6.8% Stake in Peregrine Pharmaceuticals as of Feb 21 -13D

Financial news for PPHM dated on 2017-02-09: Peregrine Pharma Reports Publication of Proof-of-Concept Data Supporting the Diagnostic Potential of Phosphatidylserine-Positive Exosomes in Ovarian Cancer

Financial news for PPHM dated on 2016-12-12: Peregrine Pharma Reports Q2 EPS \$(0.02) vs \$(0.03) Est., Sales \$23.37M vs \$18M Est.

Financial news for PPHM dated on 2016-12-12: Earnings Scheduled For December 12, 2016

Financial news for PPHM dated on 2016-11-14: UPDATE: Peregrine Says 'New Data from Second Study...Shows Triple Combination of PS-Targeting Treatment, Anti-PD-1 and Anti-LAG3 Created Long-Term Immunity in Triple Negative Breast Cancer Model'

Financial news for PPHM dated on 2016-11-14: UPDATE: Peregrine Highlights 'Promising Results of MSK Study Evaluating Combinations of PS-Targeting Treatment, Anti-PD-1 and Radiation in Mouse B16 Melanoma Model'

Financial news for PPHM dated on 2016-11-14: Peregrine Pharma Reports New Study Showed Anti-Tumor Advantages for Combo Treatment with Co.'s PS-Targeting Antibodies

Financial news for PPHM dated on 2016-10-24: Peregrine Pharmaceuticals Preclinical Research Shows PS-Targeting Antibody With Anti PD-L1 Therapy Led To Greater Anti-Tumor Activity Than Single Agent Treatment Or Dual Combinations With Chemotherapy

Financial news for PPHM dated on 2016-10-10: Peregrine Pharmaceuticals Reports The Addition Of Bavituximab To Docetaxel Did Not Result In Improvement Of Study's Primary Endpoint Of Overall Survival

Financial news for PPHM dated on 2016-09-27: Peregrine Pharmaceuticals Presents Preclinical Data Demonstrating PS-Targeting Antibodies Significantly Enhance the Anti-Tumor Activity of Multiple Checkpoint Targeting Agents in Model of Triple Negative Breast Cancer

Financial news for PPHM dated on 2016-09-21: 15 Biggest Mid-Day Gainers For Wednesday

Financial news for PPHM dated on 2016-09-21: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for PPHM dated on 2016-09-21: Peregrine Says Phase 3 SUNRISE Trial Of Bavituximab Identifies Biomarker Associated With Statistically Significant Improvement In Overall Survival

Financial news for PPHM dated on 2016-09-08: Peregrine Reaffirms FY17 Sales Outlook of \$50M-\$55M vs \$53M Est.

Financial news for PPHM dated on 2016-09-08: Peregrine Pharma Reports Q1 EPS \$(0.05) vs \$(0.04) Est., Sales \$5.609M vs \$13M Est.

Financial news for PPHM dated on 2016-09-08: Earnings Scheduled For September 8, 2016

Financial news for PPHM dated on 2016-07-14: Peregrine Pharmaceutical Reports Quarter Ended EPS \$(0.05) vs. Est. \$(0.03), Rev. \$18.78M vs. Est. \$15.8M

Financial news for PPHM dated on 2016-07-14: Peregrine Licenses Novel Exosome-Based Cancer Detection and Monitoring Technology from UT Southwestern Medical Center, Offers Value Creation And Early Partnering Opportunities

Financial news for PPHM dated on 2016-07-14: Earnings Scheduled For July 14, 2016

Financial news for PPHM dated on 2016-06-02: UPDATE: Peregrine To Discontinue Plans To Initiate Phase 2 and 3 Trials For bavituximab

Financial news for PPHM dated on 2016-06-02: Peregrine Pharmaceuticals Sees FY17 Rev. \$50-55M vs. Est. \$42M

Financial news for PPHM dated on 2016-05-20: Premarket Gainers

Financial news for PPHM dated on 2016-04-12: Peregrine Pharmaceuticals Receives Failure to Satisfy a Continued Listing Rule Notice from Nasdaq

Financial news for PPHM dated on 2016-03-09: Peregrine Pharma Reports Q4 EPS \$(0.08) Vs Est \$(0.07), Sales \$6.709M Vs Est \$7.96M

Financial news for PPHM dated on 2016-03-02: Stocks Hitting 52-Week Lows

Financial news for PPHM dated on 2016-02-26: Mid-Afternoon Market Update: Scientific Games Gains Following Q4 Results; Weight Watchers Shares Dip

Financial news for PPHM dated on 2016-02-26: Mid-Day Market Update: Peregrine Pharmaceuticals Drops Following Bad Lung Cancer News; RR Media Shares Spike Higher

Financial news for PPHM dated on 2016-02-26: Mid-Morning Market Update: Markets Open Higher; J C Penney Earnings Top Expectations

Financial news for PPHM dated on 2016-02-26: Stocks Hitting 52-Week Lows

Financial news for PPHM dated on 2016-02-26: Benzinga's Top Downgrades

Financial news for PPHM dated on 2016-02-26: 12 Stocks Moving In Friday's Pre-Market Session

Financial news for PPHM dated on 2016-02-26: Peregrine Pharmaceuticals Crashes 65% Following Bad Lung Cancer News

Financial news for PPHM dated on 2016-02-26: Roth Capital Downgrades Peregrine Pharmaceuticals to Neutral

Financial news for PPHM dated on 2016-02-26: Roth Capital Downgrades Peregrine

Pharmaceuticals to Neutral

Financial news for PPHM dated on 2016-02-25: UPDATE: Peregrine Pharma Said Avid Bioservices Had Sales Backlog in Excess of \$58M Under Committed Contracts from Existing Clients as of Feb. 1, '16

Financial news for PPHM dated on 2016-02-25: Peregrine Pharma Offers Update on Phase III SUNRISE Trial of Bavituximab: Schedules Conference Call for 4:30 p.m. EST

Financial news for PPHM dated on 2016-02-25: Peregrine Shares Halted News Pending

Financial news for PPHM dated on 2016-01-11: Peregrine Pharmaceuticals, AstraZeneca Evaluating Bavituximab Plus Durvalumab To Expand Lung Cancer Program Q1 2016

Financial news for PPHM dated on 2016-01-06: Peregrine Pharmaceuticals and National Comprehensive Cancer Network (NCCN) Form Clinical Collaboration to Evaluate Novel Cancer Treatment Combinations With Bavituximab

Financial news for PPHM dated on 2015-12-10: Peregrine Pharma Reports Q2 EPS \$(0.07) Vs Est \$(0.09), Sales \$9.523M Vs Est \$7.50M; Phase III SUNRISE Clinical Trial Expected to Complete Enrollment in Coming Weeks While New Clinical Trials Are Being Initiated--

Financial news for PPHM dated on 2015-11-24: Peregrine Pharmaceuticals on Newsletter Mention

Financial news for PPHM dated on 2015-11-09: New Preclinical Data Presented at SITC Annual Meeting Highlight Bavituximab's Enhanced Anti-Tumor Activity When Combined With Checkpoint Inhibitors in Breast Cancer and Melanoma

Financial news for PPHM dated on 2015-10-15: Peregrine Pharmaceuticals +20% Premarket Following Announcement of Collaboration With AstraZeneca

Financial news for PPHM dated on 2015-10-15: AstraZeneca, Peregrine Pharmaceuticals Increase Ongoing Immuno-Oncology Collaboration to Include Phase II Lung Cancer Combination Clinical Trial

Financial news for PPHM dated on 2015-09-09: Peregrine Pharma Reports Q1 Sales \$9.671M vs \$7M Est., Loss of \$0.08/Share, Inline

Financial news for PPHM dated on 2015-09-08: New Translational Data Highlights Bavituximab's Ability to Induce Signs of Immune Activation in Lung Cancer Tumor Samples With Negative PD-L1 Expression

Financial news for PPHM dated on 2015-08-26: Peregrine Pharmaceuticals Presents Data at Annual Immunotherapy and Vaccine Summit (ImVacS) Supporting Ability of Bavituximab to Mediate Anti-Tumor T Cell Responses Across Multiple Tumor Types

Financial news for PPHM dated on 2015-08-24: US Stock Futures Tumble, China's Shanghai Plunges 8.5%

Financial news for PPHM dated on 2015-08-24: AstraZeneca, Peregrine Pharmaceuticals to Collaborate on Immuno-Oncology Combination Clinical Trial

Financial news for PPHM dated on 2015-07-16: Hearing Noble Financial Initiates Perrigrine With Buy, \$5 PT

Financial news for PPHM dated on 2015-07-14: Peregrine Pharma Reports Q4 Sales \$9.308M vs \$6.42M Est., Net Loss of \$0.07/Share vs Loss of \$0.08/Share Est.

Financial news for PPHM dated on 2015-07-14: Earnings Scheduled For July 14, 2015

Financial news for PPHM dated on 2015-06-25: Peregrine Pharmaceuticals Granted Key European Patent for Its Lead Clinical Drug Candidate Bavituximab

Financial news for PPHM dated on 2015-06-01: Data Presentations at ASCO Demonstrate the Ability of Peregrine Pharmaceuticals' Bavituximab to Activate Tumor Targeting Immune Cells in PD-L1 Negative NSCLC Tumors

Financial news for PPHM dated on 2015-06-01: Peregrine Pharma Announces Presentations at ASCO Showed Ability of Bavituximab to Activate Tumor Target Immune Cells in PD-L1 Negative NSCLC Tumors

Financial news for PPHM dated on 2015-06-01: Peregrine Pharmaceuticals Gives Update on Expansion of Bavituximab Clinical Program

Financial news for PPHM dated on 2015-05-29: Peregrine Pharmaceuticals Enters Into Research Partnership to Investigate Novel PS-Targeting Immunotherapy Combinations

Financial news for PPHM dated on 2015-05-28: Peregrine Pharmaceuticals Shares Rise 12% After-Hours

Financial news for PPHM dated on 2015-04-21: Preclinical Data Shown at AACR Demonstrate Synergistic Anti-Tumor Effects of Peregrine Pharmaceuticals' Phosphatidylserine -Targeting Antibodies With Immune Checkpoint Inhibitors in Models of Melanoma and Breast Cancer

Financial news for PPHM dated on 2015-04-14: Peregrine Pharmaceuticals Announces Three Abstracts Accepted for Presentation at AACR 2015 Annual Meeting

Financial news for PPHM dated on 2015-04-14: Peregrine Pharmaceuticals Says May Issue, Sell Through MLV, Common Shares for Gross Proceeds of Up to \$12.3M

Financial news for PPHM dated on 2015-03-31: Peregrine Pharma Phase 2 Design Trial Underway

Financial news for PPHM dated on 2015-03-31: Perrigrine Pharm Shares Spike Higher

Financial news for PPHM dated on 2015-03-31: Peregrine Pharma Announces Positive Bavituximab Phase I Data Published in the Peer-Reviewed Journal Cancer Medicine

Financial news for PPHM dated on 2015-02-09: Morning Market Gainers

Financial news for PPHM dated on 2015-02-09: Monday Morning Movers: Achillion Up, Regulus Down Following Drug Results

Financial news for PPHM dated on 2015-02-09: Peregrine Pharma Offers Newly-Presented Data Showing Significant Enhancement in Anti-Tumor Activity Related to PD-1, CTLA-4 in Models of Breast Cancer, Melanoma

Financial news for PPHM dated on 2015-01-16: Peregrine Pharmaceuticals To Present Phase II Clinical Data As ASCO Symposium

Financial news for PPHM dated on 2015-01-08: Option Alert: Peregrine Pharmaceuticals Jan \$1.5 Call; 1,027 Contract Trade at Ask @\$0.15; Currently \$1.54

Financial news for PPHM dated on 2014-12-31: 19 Lesser-Known Biotech Stocks With Robust Drug Pipelines

Financial news for PPHM dated on 2014-12-23: S-3 Filing from Peregrine Pharma Shows Registration for \$150M Mixed Securities Shelf Offering

Financial news for PPHM dated on 2014-12-10: Peregrine Pharmaceuticals Inc. Reports Q2 EPS of \$(0.07), Inline; Revenue of \$6.30M vs \$5.82M Est

Financial news for PPHM dated on 2014-12-10: Avid Bioservices Announces Expansion Of cGMP Manufacturing Capacity

Financial news for PPHM dated on 2014-12-10: Earnings Scheduled For December 10, 2014

Financial news for PPHM dated on 2014-10-30: Peregrine Offers 'Promising Data' Related to Bavituximab Combo, Data Showed Overall Survival 12.2 Mos., Median PFS 4.8 Mos.

Financial news for PPHM dated on 2014-10-15: Morning Market Movers

Financial news for PPHM dated on 2014-10-15: Adam Feuerstein @adamfeuerstein Tweet: \$HEB reign as the champion ebola PR panderer was toppled this morning by \$PPHM

Financial news for PPHM dated on 2014-10-15: Peregrine Pharmaceuticals Announces Data to Be Published in the Journal of Immunology Research Support Phosphatidylserine (PS) as a Potential Target in Ebola Infection

Financial news for PPHM dated on 2014-09-09: Peregrine Pharmaceuticals Inc. Reports Q1 EPS of \$(0.08) vs \$(0.06) Est; Revenue of \$5.50M vs \$6.03M Est

Financial news for PPHM dated on 2014-09-09: Earnings Scheduled For September 9, 2014

Financial news for PPHM dated on 2014-08-11: Preclinical Data Presented at Annual Immunotherapies and Vaccine Summit Show Combination of Peregrine Pharmaceuticals' PS-Targeting Antibodies and Anti-PD-1 Antibodies Significantly Reduce Breast Cancer Progression

Financial news for PPHM dated on 2014-07-14: Peregrine Pharmaceuticals Inc. Sees FY2015 Contract Manufacturing Sales \$19.0M-23.0M

Financial news for PPHM dated on 2014-07-14: Peregrine Pharmaceuticals Inc. Reports Q4 EPS of \$(0.06) vs \$(0.07) Est; Revenue of \$6.47M vs \$4.75M Est

Financial news for PPHM dated on 2014-07-14: Earnings Scheduled For July 14, 2014

Financial news for PPHM dated on 2014-04-23: Peregrine Pharmaceuticals Announces Investigator-Sponsored Trial Combining Immunotherapy Bavituximab, Ipilimumab

Financial news for PPHM dated on 2014-04-16: Sub \$5 Stocks With Expected Return Of Over 50% In 2014: Investment Idea Of The Day

Financial news for PPHM dated on 2014-04-09: UPDATE: Peregrine Pharma Reports Data on Bavituximab Presented at AACR Validates Immune-Stimulatory Mechanism of Action

Financial news for PPHM dated on 2014-04-09: Data Presented at AACR Support Potential of Peregrine's PS-Targeting Immunotherapy Bavituximab to Enhance Anti-Tumor and Immune-Stimulating Effects of Anti-CTLA-4 and Anti-PD-1 Treatments in Models of Melanoma and Colon Cancer

Financial news for PPHM dated on 2014-04-09: Perrigrine Pharmaceutical Shares Move Higher on Volume

Financial news for PPHM dated on 2014-04-07: Morning Market Movers

Financial news for PPHM dated on 2014-03-11: Mid Morning Gainers for March 11th, 2014

Financial news for PPHM dated on 2014-03-11: Peregrine Pharma Announces PS-Targeting Antibodies to Overcome Immunesuppression, Cites Preclinical Cancer Models

Financial news for PPHM dated on 2014-03-11: McNicoll Lewis Vlak Maintains Buy on Peregrine Pharmaceuticals Inc., Raises PT to \$3.50

Financial news for PPHM dated on 2014-03-10: Mid-Afternoon Market Update: 3D Printing Names Take a Hit From Barron's Piece as Fuel Cell Names Continue Rally

Financial news for PPHM dated on 2014-03-10: Mid-Day Market Update: Chiquita Gains On Merger News; Cliffs Natural Shares Drop

Financial news for PPHM dated on 2014-03-10: Mid-Morning Market Update: Markets Open Lower; McDonald's Comparable Sales Fall 0.3%

Financial news for PPHM dated on 2014-03-07: Peregrine Pharmaceuticals Inc. Reports Q3 EPS of \$(0.06), Inline; Revenue of \$3.89M vs \$5.09M Est

Financial news for PPHM dated on 2014-03-07: Earnings Scheduled For March 7, 2014

Financial news for PPHM dated on 2014-02-11: Peregrine Pharma Prices Offering of Series E Preferred Shares, 700K Shares Convertible at \$25/Share

Financial news for PPHM dated on 2014-02-04: Peregrine Pharmaceuticals Spikes Higher; May be Attributed to Unemon Post

Financial news for PPHM dated on 2014-01-13: Perrigrine Pharmaceuticals Spikes Higher on CNBC Comments

Financial news for PPHM dated on 2014-01-13: Perrigrine Pharm Spikes Higher

Financial news for PPHM dated on 2014-01-06: Morning Market Movers

Financial news for PPHM dated on 2014-01-06: Peregrine Pharma Reports FDA Fast Track Designation for Bavituximab

Financial news for PPHM dated on 2013-12-30: Peregrine Pharmaceuticals Initiates Sunrise Pivotal Phase III Clinical Trial of Bavituximab in Second-Line Non-Small Cell Lung Cancer

Financial news for PPHM dated on 2013-12-27: Peregrine Pharma Files \$100M Stock, Preferred Stock Shelf

Financial news for PPHM dated on 2013-12-10: Peregrine Pharmaceuticals Inc. Reports Q3 EPS of \$(0.05), Inline; Revenue of \$7.35M vs \$5.74M Est

Financial news for PPHM dated on 2013-12-10: Earnings Scheduled For December 10, 2013

Financial news for PPHM dated on 2013-11-08: Peregrine's Bavituximab in Combination With Anti-CTLA-4 Antibodies Yields Enhanced Anti-Tumor Activity in Pre-Clinical Model of Melanoma

Financial news for PPHM dated on 2013-11-08: Peregrine Says Data for Novel Immunotherapy Bavituximab in Combo with Anti-CTLA-4 Antibodies Supports Potential Use, Planning Phase III Trial by End of This Year

Financial news for PPHM dated on 2013-09-09: Peregrine Pharmaceuticals Inc. Reports Q1 EPS of \$(0.05), Inline; Revenue of \$4.69M vs \$4.75M Est

Financial news for PPHM dated on 2013-09-09: Earnings Scheduled For September 9, 2013

Financial news for PPHM dated on 2013-07-11: Peregrine Pharmaceuticals Inc. Reports Q4 EPS of \$(0.06), Inline; Revenue of \$4.25M vs \$3.57M Est

Financial news for PPHM dated on 2013-07-11: Earnings Scheduled For July 11, 2013

Financial news for PPHM dated on 2013-06-27: Market Wrap for Thursday, June 27: Stock Market Rally Picks Up Momentum

Financial news for PPHM dated on 2013-06-27: Afternoon Market Losers

Financial news for PPHM dated on 2013-06-27: Perrigrine Pharmaceuticals Shares Fall 17% Pre-Market on Disappointing Bavituximab Trial Data

Financial news for PPHM dated on 2013-06-27: Peregrine Pharmaceuticals Provides Update on Bavituximab Clinical Program

Financial news for PPHM dated on 2013-06-03: Afternoon Market Gainers

Financial news for PPHM dated on 2013-06-03: Morning Market Movers

Financial news for PPHM dated on 2013-06-03: Peregrine Pharma Issues Promising 11.7 Month Median Overall Survival Data in Second-Line NSCLC Patients Treated with Bavituximab

Financial news for PPHM dated on 2013-05-20: Shares of Peregrine Pharma Resume Trade Up 20%

Financial news for PPHM dated on 2013-05-20: Shares of Peregrine Pharma to Resume Trade at 9:15AM EDT

Financial news for PPHM dated on 2013-05-20: Peregrine Pharmaceuticals Reaches Agreement With FDA on a Phase III Trial Design for Bavituximab in Second-Line Non-Small Cell Lung Cancer

Financial news for PPHM dated on 2013-05-20: Peregrine Pharma Announces Deal with FDA on Phase II Study Deesign for Bavituximab

Financial news for PPHM dated on 2013-05-20: Peregrine Pharma Shares Halted News PENDING

Financial news for PPHM dated on 2013-04-29: Peregrine Closes Patient Enrollment in Breast Cancer Clinical Trial for Bavituximab

Financial news for PPHM dated on 2013-04-10: Peregrine Pharmaceuticals Hosts Annual Meeting; Highlights Bavituximab's Potential in Solid Tumor Therapy

Financial news for PPHM dated on 2013-03-12: Peregrine Pharma Says Data Supports C Bavituximab into Phase III

Financial news for PPHM dated on 2013-03-12: Peregrine Pharmaceuticals Inc. Reports Q3 EPS of \$(0.04) vs \$(0.07) Est

Financial news for PPHM dated on 2013-03-12: Earnings Scheduled For March 12, 2013

Financial news for PPHM dated on 2013-03-06: UPDATE: Piper Jaffray Initiates Peregrine Pharmaceuticals with Overweight on Attractive Risk-Reward Opportunities

Financial news for PPHM dated on 2013-03-05: Piper Jaffray Initiates Coverage on Peregrine Pharmaceuticals Inc. at Overweight, Announces \$2.50 PT

Financial news for PPHM dated on 2013-02-19: Peregrine Pharma Offers Update for Top-Line Data from Phase II Trial of Bavituximab

Financial news for PPHM dated on 2013-02-13: Peregrine Pharma Shares Surge 20% Following Results from Phase 2 Trial of Bavituximab

Financial news for PPHM dated on 2013-02-13: Peregrine Pharma Reports Results from Phase 2 Trial of Bavituximab, Says Topline Demonstrates Signs of Anti-Tumor Activity

Financial news for PPHM dated on 2013-01-25: Peregrine Pharmaceuticals Finds Its Stride Again: Exclusive Interview With MLV & Co's George Zavoico

Financial news for PPHM dated on 2013-01-08: Peregrine Pharmaceuticals Soars 80% on

## Study Review

Financial news for PPHM dated on 2013-01-07: Major Averages Record Small Losses to Start Week

Financial news for PPHM dated on 2013-01-07: Roth Capital Upgraded Peregrine Pharma Following Internal Review of Trial

Financial news for PPHM dated on 2013-01-07: Morning Market Movers

Financial news for PPHM dated on 2013-01-07: Peregrine Pharma Issues Update on Internal Review of Phase II Second-Line Non-Small Cell Lung Cancer Trial

Financial news for PPHM dated on 2012-12-11: Peregrine Regains Compliance With NASDAQ Minimum Bid Price Listing Requirement

Financial news for PPHM dated on 2012-12-10: Peregrine Pharmaceuticals Inc. Reports Q2 EPS of \$(0.08) vs \$(0.09) Est; Revenue of \$6.14M vs \$4.03M Est

Financial news for PPHM dated on 2012-12-10: Earnings Scheduled For December 10, 2012

Financial news for PPHM dated on 2012-12-07: The Week Ahead: Washington in Focus

Financial news for PPHM dated on 2012-12-05: Peregrine Shares Higher as Co. Reports Significant Progress in Advancing Cotara Program Into Pivotal Phase III Trial

Financial news for PPHM dated on 2012-10-17: Benzinga's Microcap Movers for Wednesday October 17, 2012

Financial news for PPHM dated on 2012-10-17: Peregrine Pharma Says Funding Should be Fine Through Q3 of 2013

Financial news for PPHM dated on 2012-10-05: Milberg LLP Announces Pendency of Class Action Lawsuits Filed Against Peregrine Pharmaceuticals

Financial news for PPHM dated on 2012-09-27: Advanced BioScience Laboratories Awards Avid Bioservices HIV Vaccine Development and Manufacturing Contract

Financial news for PPHM dated on 2012-09-27: Peregrine Pharmaceuticals Falls 30% Pre-Market on Capital Fears

Financial news for PPHM dated on 2012-09-26: Benzinga Mid-Day Market Update

Financial news for PPHM dated on 2012-09-26: Benzinga Mid-Morning Market Update

Financial news for PPHM dated on 2012-09-25: Bronstein, Gewirtz & Grossman Announces Investigation of Peregrine Pharmaceuticals

Financial news for PPHM dated on 2012-09-24: Benzinga Mid-Afternoon Market Update

Financial news for PPHM dated on 2012-09-24: Mid-Day Market Losers

Financial news for PPHM dated on 2012-09-24: Benzinga Mid-Day Market Update

Financial news for PPHM dated on 2012-09-24: Morning Market Losers

Financial news for PPHM dated on 2012-09-24: UPDATE: Roth Capital Downgrades Peregrine Pharmaceuticals Downgrades from Buy to Neutral

Financial news for PPHM dated on 2012-09-24: Roth Capital Downgrades Peregrine Pharmaceuticals Downgrades from Buy to Neutral

Financial news for PPHM dated on 2012-09-24: Peregrine Pharmaceuticals Falls 76% on Data Warning

Financial news for PPHM dated on 2012-09-24: Peregrine Pharmaceuticals Resumes Trading

Financial news for PPHM dated on 2012-09-24: PREVIEW: Peregrine Pharmaceuticals to Resume Trading at 8:00am

Financial news for PPHM dated on 2012-09-24: Peregrine Pharma Says Discovered Major Discrepancies in Control Group; Investors Shouldn't Rely on Phase 2 Data

Financial news for PPHM dated on 2012-09-24: Peregrine Pharmaceuticals Halted; Pending News

Financial news for PPHM dated on 2012-09-20: Hearing Peregrine Pharmaceuticals Cancels Out of Investor Meeting Due to Scheduling Conflict



Financial news for PPHM dated on 2012-09-10: Peregrine Pharmaceuticals Spiking Higher Ahead of 11am Conference Call

Financial news for PPHM dated on 2012-09-10: Peregrine Pharmaceuticals Reports Q1 EPS \$-0.07 vs \$-0.11 Est; Revenues \$4.25M vs \$3.96M Est

Financial news for PPHM dated on 2012-09-10: Benzinga's Top Pre-Market Gainers

Financial news for PPHM dated on 2012-09-10: PREVIEW: Peregrine Pharmaceuticals Q1 2013 Financial Results Conference Call at 11:00am ET

Financial news for PPHM dated on 2012-09-10: Peregrine Pharmaceuticals Rises 10% Pre-Market

Financial news for PPHM dated on 2012-09-10: Earnings Scheduled For September 10, 2012

Financial news for PPHM dated on 2012-09-07: Peregrine Pharmaceuticals Pre-Recorded Webcast Begins

Financial news for PPHM dated on 2012-09-07: Peregrine Pharmaceuticals Crosses \$5

Financial news for PPHM dated on 2012-09-07: Peregrine Pharmaceuticals Resumes Trading

Financial news for PPHM dated on 2012-09-07: Peregrine Pharmaceuticals Halted; Circuit Breaker

Financial news for PPHM dated on 2012-09-07: Peregrine Pharmaceuticals Spikes Higher

Financial news for PPHM dated on 2012-09-07: Peregrine Pharmaceuticals Resumes Trading

Financial news for PPHM dated on 2012-09-07: PREVIEW: Peregrine Pharmaceuticals to Resume Trading at 1:20pm ET

Financial news for PPHM dated on 2012-09-07: Peregrine Pharma Says Phase II Trial Shows Doubling of Survival

Financial news for PPHM dated on 2012-09-07: Peregrine Pharma Doubles Lung Cancer Survival Rate in Small Trial -Reuters

Financial news for PPHM dated on 2012-09-07: Peregrine Doubles Lung Cancer Survival in Small Trial

Financial news for PPHM dated on 2012-09-07: UPDATE: Peregrine Pharmaceuticals Halted; Presentation of Data at 2:40pm

Financial news for PPHM dated on 2012-09-07: Peregrine Pharmaceuticals Halted; Pending News

Financial news for PPHM dated on 2012-09-07: Peregrine Pharmaceuticals Spikes Lower

Financial news for PPHM dated on 2012-08-30: Peregrine Pharmaceuticals Secures \$30 Million Loan Facility

Financial news for PPHM dated on 2012-08-30: Peregrine Pharmaceuticals Secures \$30 Million Loan Facility

Financial news for PPHM dated on 2012-08-17: Roche to Partner with Peregrine Pharmaceuticals -Sierra World Equity Review

Financial news for PPHM dated on 2012-08-14: Peregrine Pharmaceuticals Rises 21% Pre-Market

Financial news for PPHM dated on 2012-08-14: Peregrine Pharmaceuticals Rises 7% Pre-Market

Financial news for PPHM dated on 2012-07-17: Peregrine Pharmaceuticals Soars After Smaller Than Expected Loss

Financial news for PPHM dated on 2012-07-16: Peregrine Pharmaceuticals Reports Q4 EPS \$-0.10 vs \$-0.13 Est; Revenues \$2.1M vs \$2.64M Est

Financial news for PPHM dated on 2012-07-16: Peregrine Announces Initiation of a Phase I Rectal

Financial news for PPHM dated on 2012-07-16: Earnings Scheduled For July 16

Financial news for PPHM dated on 2012-07-13: Peregrine Pharmaceuticals Continues Strong Momentum; Shares up 14%

Financial news for PPHM dated on 2012-06-28: Ultimate Stock Watch List for The Supreme Court's Health Care Ruling

Financial news for PPHM dated on 2012-06-11: Avid Bioservices Announces Addition of Novel Bacteriophage

Financial news for PPHM dated on 2012-05-21: Peregrine Announces Positive Top-Line Data From Randomized, Double-Blind Bavituximab Phase II Trial in Second-Line Non-Small Cell Lung Cancer

Financial news for PPHM dated on 2012-04-13: LifeTech Capital Downgrades Peregrine Pharmaceuticals from Strong Buy to Neutral, Lowers PT from \$5 to \$0.5

Financial news for PPHM dated on 2012-03-28: Peregrine Pharma Minimum Bid Notice

Financial news for PPHM dated on 2012-03-12: Peregrine Pharma Removed From Focus List at Roth Capital

Financial news for PPHM dated on 2012-03-09: Peregrine Reports Data From Phase II Front-Line Lung Cancer Trial; Promising Progression-Free Survival From Site Assessments

Financial news for PPHM dated on 2011-12-29: UPDATE: Peregrine Says Preliminary Data From Phase II Study Shows Antiviral Activity and Positive Safety Profile at Both Bavituximab Doses Evaluated

Financial news for PPHM dated on 2011-12-29: Peregrine Provides Update on HCV Clinical Program

Financial news for PPHM dated on 2011-12-12: Peregrine Pharmaceuticals Reports Q2 EPS \$(0.16) vs \$(0.14) Est; Revenues \$4.23M vs \$2.08M Est

Financial news for PPHM dated on 2011-12-07: Investor Ideas: Tuesday's Biotech and Pharma Stocks to Watch

Financial news for PPHM dated on 2011-12-06: Microcap Movers for Tuesday December 6, 2011

Financial news for PPHM dated on 2011-12-06: Is This Drug About to Cure Cancer?

Financial news for PPHM dated on 2011-12-06: Peregrine's Bavituximab Shows 50% Improvement in Overall Tumor Response Rate in Randomized Phase II Lung Cancer Trial

Financial news for PPHM dated on 2011-11-22: Peregrine Reports Promising 23.2 Month Median Overall Survival From Phase II Advanced Breast Cancer Trial

Financial news for PPHM dated on 2011-10-06: Peregrine Completes Patient Enrollment in Second-Line Non-Small Cell Lung Cancer Trial; Data to Be Unblinded in First Half 2012

Financial news for PPHM dated on 2011-09-26: Peregrine Completes Patient Enrollment in Randomized Phase II HCV Trial for Bavituximab

Financial news for PPHM dated on 2011-09-08: McNicoll, Lewis & Vlasko Maintains Peregrine Pharmaceuticals Buy, PT

Financial news for PPHM dated on 2011-09-08: Peregrine Completes Patient Enrollment in Randomized Phase II Trial for Bavituximab in Front-Line Non-Small Cell Lung Cancer

Financial news for PPHM dated on 2011-09-02: Market Update

Financial news for PPHM dated on 2011-09-02: Peregrine Prices \$7 Million Registered Direct Offering of Common Stock at \$1.11/Share

Financial news for PPHM dated on 2011-08-24: McNicoll, Lewis & Vlasko Maintains Peregrine Pharmaceuticals Buy, PT

Financial news for PPHM dated on 2011-08-24: Morning Market Movers

Financial news for PPHM dated on 2011-08-16: Midday Gainers; Carbonite up 18% on Heavy Volume

Financial news for PPHM dated on 2011-07-18: UPDATE: MLV Lowers PT on Peregrine Pharmaceuticals to \$8.50

Financial news for PPHM dated on 2011-06-15: Peregrine Reports Promising 12.4 Month Overall Survival Data From Phase II Trial in Non-Small Cell Lung Cancer

Financial news for PPHM dated on 2011-06-03: Peregrine Presents Promising Phase II Survival Data in Recurrent GBM With Single Treatment of Cotara at ASCO Annual Meeting

Financial news for PPHM dated on 2011-04-05: Morning Roundup: Top-5 and Bottom-5 Percentage Gainers (CBST, QCOR, SNSS, PPHM, EXPE, LEDS, MERU, PSEC, CREE, AIXG)

Financial news for PPHM dated on 2011-01-13: Wave Systems, Biodel: Small-Cap Winners

Financial news for PPHM dated on 2010-12-14: Life Tech Capital Reiterates Strong Buy on Peregrine Pharma (PPHM)

Financial news for PPHM dated on 2010-12-10: Loss at PPHM Wider than Expected - Analyst Blog

Financial news for PPHM dated on 2010-12-10: Loss at PPHM Wider than Expected - Analyst Blog

Financial news for PPHM dated on 2010-07-14: Peregrine Pharma's Revenues and EPS Miss Estimates (PPHM)

Financial news for PPHM dated on 2010-06-24: Buy This Cancer Stock Today (PPHM)

Financial news for PPHM dated on 2010-06-24: Puts Sold on Peregrine Pharmaceuticals (PPHM)

Financial news for PPHM dated on 2010-04-14: Initiated BUY on Peregrine Pharmaceuticals (PPHM)

Financial news for PPHM dated on 2010-01-11: PPHM Skyrockets As New Head Of Clinical Science Joins

Financial news for PPHM dated on 2009-08-17: AnalystChoice.com Brings You the Best Complimentary Research Report on PPHM, OCLS, FISV, SNPS, FMCN and PETM